YXYibei Xiao

Yibei Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yibei Xiao has a total of 307 co-authors. Here are the top co-authors by number of shared publications:

  • Zhaoxing Li

    State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, China

    10 shared publications
  • Meiling Lu

    State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China

    9 shared publications
  • Meiling Lu

    Department of Biochemistry, School of Life Science and Technology, China, Pharmaceutical University , Nanjing 211198

    9 shared publications
  • Pingping Huang

    State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China

    9 shared publications
  • Wanqian Wu

    State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing, China

    8 shared publications
  • Meirong Chen

    State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University , Nanjing 211198

    7 shared publications

Latest Publications

  • Open Access

    Structural basis for ITP-selective hydrolysis by a CRISPR-associated Nudix hydrolase

    by Wanqian Wu, Shenglan Xia, Duo Li, Junchao Lin, Chen Cao, Jianping Kong, Meiling Lu, Yibei Xiao, Zhaoxing Li

    The nucleoside diphosphates linked to moiety-X (Nudix) hydrolases are a superfamily of proteins defined by the characteristic Nudix box sequence, most of which are involved in clearing the cell of potentially deleterious metabolites and in preventing the accumulation of metabolic intermediates. The Nudix hydrolase associated with CRISPR-Cas-associated adenosine deaminases (CAAD) from Limisphaera ngatamarikiensis ( Lng NH) mitigates CAAD-induced toxicity by hydrolyzing ITP to IMP and pyrophosphate. Here, we determined crystal structures of Lng NH in the apo form and in complex with ITP using catalytic mutants and validated key interactions by site-directed mutagenesis. The hypoxanthine of ITP is deeply buried in a hydrophobic pocket and engages a distinct hydrogen-bond network, whereas the triphosphate tail is coordinated by conserved residues and divalent metal ions. Together, these findings provide a structural framework for CAAD-linked nucleotide sanitization and suggest that CRISPR-associated Nudix hydrolases function as local self-protection modules that limit toxicity from noncanonical inosine nucleotides. IMPORTANCE: Nucleotide quality-control enzymes protect cells from harmful metabolic by-products. Here, we characterize a CRISPR-associated nucleoside diphosphates linked to moiety-X (Nudix) hydrolase that removes ITP, a toxic noncanonical nucleotide generated during antiviral defense. Biochemical and structural analyses show how this enzyme specifically recognizes and hydrolyzes ITP while avoiding related cellular nucleotides. Our findings suggest that CRISPR-associated nucleotide deaminase systems require “self-protection” mechanisms to prevent damage from their own antiviral activities. These results expand our understanding of how bacteria maintain nucleotide homeostasis during immune responses and reveal an additional regulatory layer within CRISPR-associated defense systems. The structural framework reported here also provides a foundation for future studies of nucleotide sanitization enzymes in microbial physiology and antiviral immunity.

  • Open Access

    A molecular glue induces aberrant STING oligomerization and inhibits autoinflammatory diseases

    by Zi-Wen Feng, Ting Zeng, Qing Shu, Xiao-Zhong Li, Hai-Guo Yu, Wei Dai, Xue-Chun Liu, Xin-Jian Tian, Feng Xu, Hui Li, et al.

  • Crystal structure of the cytosolic Nudix-like domain of CD-NTase-associated protein 16 from Enterococcus faecalis

    by Tinashe Makanyire, Zihan Zhou, Wanqian Wu, Mingyan Li, Shenglan Xia, HaoYuan Shi, Jianping Kong, Zhaoxing Li, Yibei Xiao

    The cyclic oligonucleotide-based antiphage signaling system (CBASS) employs diverse effector proteins to trigger abortive infection upon phage invasion, yet structural information on membrane-associated CBASS effectors remains limited. CD-NTase-associated protein 16 from Enterococcus faecalis ( Ef Cap16) is a predicted CBASS effector comprising an N-terminal transmembrane region and a C-terminal Nudix-like domain. Here, we report the recombinant expression, purification, crystallization and X-ray crystal structure of the cytosolic Nudix domain of Ef Cap16 (PDB entry 22lg) in space group P 12 1 1. The protein was purified to homogeneity and crystallized, and its structure was determined at 1.6 Å resolution. The Ef Cap16 Nudix domain shares structural similarity with the Nudix superfamily and contains a conserved Nudix motif. This structure provides a reference framework for future biochemical and functional studies of transmembrane CBASS effectors.

  • The antiphage mechanism of a widespread trypsin–MBL defense module

    by Pingping Huang, Jingxian Liu, Lijie Guo, Dongyang Xu, Lingbo Shen, Purui Yan, Chen Tong, Wenying Fei, Mengjun Cheng, Zhaoxing Li, et al.

    Protease-mediated activation of immune effectors is an evolutionarily conserved mechanism. This study identifies a widespread trypsin-MBL (metallo-β-lactamase) module as a core effector in diverse antiviral bacterial immune systems, such as Hachiman, AVAST and Argonaute. Focusing on the Hachiman-associated trypsin-MBL system, we show that trypsin•HamAB protease activity is inhibited by ATP, while MBL is an autoinhibited DNase with two insertion loops obstructing its catalytic site. Upon infection, trypsin•HamAB senses foreign DNA and hydrolyzes ATP, activating trypsin-like activity, which specifically cleaves MBL at the insertion loops to release repression. The activated MBL depletes DNA and arrests host cell growth. Cryo-electron microscopy structures of trypsin•HamAB-DNA reveal that DNA binding and ATP hydrolysis trigger HamAB oligomerization and trypsin-like domain release, enabling its activation. Our work elucidates a conserved immune mechanism wherein proteolytic activation of a nuclease enables robust immunity against phage while multilayered controls prevent self-toxicity, expanding the repertoire of immune processes governed by regulatory proteolysis.

  • Open Access

    Rational design of carbazole-based STING inhibitors for treating cGAS-STING pathway-driven inflammatory disorders

    by Hui Li, Wei Zheng, Wenjing Bian, Mei Li, Zhidan Fan, Ziwen Feng, Xiaoyan Liu, Shiduo Zhang, Haohao Lu, Yinquan Huang, et al.

    Stimulator of Interferon Genes (STING) is a pivotal adaptor protein in the innate immune pathway, and its aberrant activation is closely associated with the pathogenesis of autoimmune diseases. Although it has emerged as an attractive therapeutic target for inflammatory disorders, current STING inhibitors still face challenges including off-target toxicity and limited understanding of binding mechanism. Herein, through a Target & Cell-based cascade screening and rational design, DDO-88109 with a carbazole scaffold is identified as a STING inhibitor, with IC50 values of 1.76 μM and 1.85 μM in THP1-Dual and RAW-Lucia ISG cells, respectively. Moreover, DDO-88109 shows broad affinity for hSTING isoforms (WT, HAQ, and H232) and suppresses the activation of the cGAS-STING signaling pathway with favorable selectivity. Structurally, DDO-88109 occupies the CDN-binding pocket of STING in a 2:1 stoichiometry determined by co-crystal structure study. In TREX1 deficiency driven autoinflammation and cisplatin-induced AKI male mice models, treatment with DDO-88109 (15 mg/kg) significantly reduces the secretion of inflammatory factors and ameliorates tissue inflammation. Collectively, the discovery of DDO-88109 establishes a paradigm for structure-based rational drug development of STING inhibitors to provide potential small-molecule therapeutics against cGAS-STING signaling driven human autoimmune diseases.


  • Structural and functional characterization of SPARTA system

    by Hongze Zhao, Pingping Huang, Lijie Guo, Xinning Jiang, Zhaoxing Li, Bingjie Tao, Meiling Lu, Lianwen Qi, Lei Zhang, Yibei Xiao, et al.

  • Open Access

    Structural and functional insights into the adenosine deaminase of the type III-B CRISPR–Cas system

    by Zhaoxing Li, Jianping Kong, Wanqian Wu, Yan Duan, Ziyi Zhu, Chenyang Hua, Purui Yan, Chen Cao, Xu Cao, Yibei Xiao, et al.

    Type III CRISPR–Cas (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins) systems confer antiviral immunity via cyclic oligoadenylate (cOA) signaling. Here, we elucidate a cooperative bacterial defense strategy involving two cOA-activated CRISPR-associated Rossmann fold (CARF)-containing effectors, adenosine deaminase CAAD and ribonuclease Csx1, in Thermoanaerobaculum aquaticum. Genomic analyses indicate widespread co-occurrence of CRISPR-associated adenosine deaminase (CAAD) with ancillary CARF-containing effectors in type III CRISPR systems, suggesting that multiple CARF-containing proteins may contribute to a coordinated cOA-dependent defense. Biochemical and structural studies reveal the intrinsic dynamics of CAAD hexamer, and demonstrate that cA4/cA6 binding stabilizes CAAD hexamers, triggering metal-ion-dependent conversion of ATP into inosine triphosphate. Concurrently, the downstream Csx1 is exclusively activated by cA4 to cleave single-stranded RNA. Strikingly, we found that both effectors are capable of degrading cA4, suggesting that this CAAD–Csx1 pair may be cross-regulated and achieve immunity through a dual-targeting mechanism: in response to infection, Csx1 degrades viral RNA while CAAD disrupts nucleotide metabolism via ATP deamination, which can be relieved via cA4 degradation when infection has been eliminated. This study proposes an enhanced defense mechanism through coordinated activation and regulation of multiple CRISPR effectors by a single signaling molecule, unveiling unprecedented complexity in CRISPR immunoregulation.

  • Structural basis for Cas9-directed spacer acquisition in type II-A CRISPR-Cas systems

    by Zhaoxing Li, Yutao Li, Jianping Kong, Qianqian Wu, Pingping Huang, Yu Zhang, Wanqian Wu, Meirong Chen, Yongfeng Liu, HanFeng Lin, et al.


  • Open Access

    Structural plasticity enables broad cA n binding and dual activation of CRISPR-associated ribonuclease Cdn1

    by Wenxuan Zhang, Jianping Kong, Yuqin Zeng, Yunning Su, Sijun Zhang, Yutao Li, Chunyi Hu, Qihua Chen, Yibei Xiao, Meiling Lu

    Prokaryotes have naturally evolved diverse RNA-guided defense systems against viral infections, with the type III CRISPR–Cas systems representing the most intricate. These systems feature accessory proteins activated by cyclic oligoadenylates (cOAs) produced upon target RNA recognition, synergizing with the CRISPR–Cas machinery to defend against exogenous invaders. Typically, each accessory protein is activated by only one specific cOA type. Here, we characterize Cdn1, a type III-B CRISPR accessory protein from Psychrobacter lutiphocae, which binds to cA3, cA4, and cA6, but activated by cA4 and cA6 with different efficacies to catalyze ssRNA cleavage. Combined structural and biochemical analyses reveal that cOA binding triggers dramatic conformational reorganization, including the formation of a dimerization interface of nuclease domains, the emergence of substrate binding cleft, and the reconstruction of a metal-dependent catalytic center essential for RNA cleavage. This dual activation mechanism illustrates evolutionary innovation within CRISPR-associated Rossman-fold nucleases. We propose that such structural plasticity evolved to maximize defensive resilience during microbial competition and horizontal gene transfer, while preserving broad-spectrum antiviral ability. These findings not only elucidate the activation mechanisms of Cdn1 within the type III systems but also underscore the functional complexity and adaptability of CRISPR–Cas ancillary proteins.

  • Open Access

    Targeting PTPN2-mediated dephosphorylation destabilizes c-MYC and suppresses acute myeloid leukemia survival

    by Wenbin Kuang, Dawei Wang, Mingge Song, Jianing Liu, Jiaxing Li, Wenmu Wang, Anyan Chen, Ya Chen, Jiayu Ding, Liping Wang, et al.

    Acute myeloid leukemia (AML) is a fatal disease characterized by a bleak prognosis. For over four decades, treatment options for AML have been constrained to administering high-dose cytotoxic chemotherapy. However, the emergence of drug resistance and the resultant toxic side effects have created an urgent necessity for identifying novel therapeutic targets. In this study, non-receptor protein tyrosine phosphatase type 2 (PTPN2) is highly expressed in AML. Remarkably, knockdown of PTPN2 expression markedly mitigated AML burden both in vitro and in vivo. Additionally, we unveiled the direct interaction between PTPN2 and c-MYC, establishing c-MYC as a direct acting substrate of PTPN2. Then, we obtained a small-molecule inhibitor, WS35, which has good inhibitory activity against PTPN2. Moreover, WS35 shows a strong therapeutic effect in vivo for AML. In conclusion, these results indicate the carcinogenic mechanism of PTPN2, and the therapeutic strategies targeting PTPN2 have significant potential for treating AML.